Caris Life Sciences, Inc. Income Statement
CAI / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Caris Life Sciences, Inc. reported $812M in revenue and $68M in net loss for FY2025. Revenue has grown at a 62.9% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $812.0M | $412.3M | $306.1M |
| SG&A Expense | $225.0M | $169.4M | $149.1M |
| R&D Expense | $101.6M | $113.9M | $116.9M |
| Operating Income | $45.1M | -$257.1M | -$319.6M |
| Interest Expense | $56.8M | $50.0M | $31.5M |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$68.1M | -$281.9M | -$341.4M |
| EPS (Basic) | -$13.24 | -$10.66 | -$13.24 |
| EPS (Diluted) | -$13.24 | -$10.66 | -$13.24 |
| Shares Outstanding | 36.5M | 35.5M | 34.9M |
| Operating Margin | 5.6% | -62.4% | -104.4% |
| Profit Margin | -8.4% | -68.4% | -111.5% |